Literature DB >> 8244260

Activation of the fibrinolytic system in patients with fulminant liver failure.

J R Pernambuco1, P G Langley, R D Hughes, S Izumi, R Williams.   

Abstract

Abnormalities of blood coagulation and fibrinolysis are a major part of fulminant liver failure. In this study, the key components of the fibrinolytic system were determined in 42 patients with this condition. Admission levels of plasma plasminogen activity were low (9.1% of normal), as to a lesser extent were the activities of its inhibitors alpha 2-antiplasmin (20.5% of normal) and C1 inhibitor (64% of normal). Tissue plasminogen activator activity was found at normal levels, whereas the level of its fast inhibitor, plasminogen activator inhibitor-1, was greatly increased compared with that of controls (24.3 U/ml and 7.4 U/ml, respectively), indicating a shift toward inhibition of fibrinolysis in these patients. Thrombin-antithrombin complex levels in plasma were significantly increased in fulminant liver failure compared with those in controls (33.5 micrograms/L vs. 2.5 micrograms/L, p < 0.001), indicating activation of coagulation in these patients. High plasma levels of D-dimer, a fragment of cross-linked fibrin, were also found (1,510 micrograms/L vs. 33 micrograms/L in controls, p < 0.001); this finding correlated with the increased level of thrombin-antithrombin complex (r = 0.61, p < 0.001), consistent with activation of fibrinolysis resulting from intravascular coagulation. In conclusion, there are gross abnormalities of the fibrinolytic system in fulminant liver failure, but because inhibitory activity appears to be present in adequate quantities, this limits the incidence of bleeding due to fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244260

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 2.  Criteria for specific measurement of plasminogen (enzymatic; procedure) in human plasma.

Authors:  Johannes J Sidelmann; Nuala A Booth; Johannes Hoffmann; Michael E Nesheim; Steffen Rosén
Journal:  EJIFCC       Date:  2000-09-01

3.  The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.

Authors:  Nikita Joshi; Anna K Kopec; Keara Towery; Kurt J Williams; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-03-14       Impact factor: 4.030

4.  Fibrinogen-γ proteolysis and solubility dynamics during apoptotic mouse liver injury: heparin prevents and treats liver damage.

Authors:  Sujith V W Weerasinghe; David S Moons; Peter J Altshuler; Yatrik M Shah; M Bishr Omary
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

5.  Plasminogen Activator Inhibitor-1 Reduces Tissue-Type Plasminogen Activator-Dependent Fibrinolysis and Intrahepatic Hemorrhage in Experimental Acetaminophen Overdose.

Authors:  Asmita Pant; Anna K Kopec; Kevin S Baker; Holly Cline-Fedewa; Daniel A Lawrence; James P Luyendyk
Journal:  Am J Pathol       Date:  2018-02-16       Impact factor: 4.307

Review 6.  Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management.

Authors:  Rabia Islam; Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Ibrahim Sange
Journal:  Cureus       Date:  2022-04-03

Review 7.  The contact system in liver injury.

Authors:  Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Sandra Konrath; Thomas Renné
Journal:  Semin Immunopathol       Date:  2021-06-14       Impact factor: 9.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.